The news directly pertains to Cerevel Therapeutics Hldg (CERE) as Mizuho has maintained a Neutral rating on the company and lowered the price target. This could potentially influence investor sentiment and the stock's market performance. However, as the rating remains Neutral, the immediate impact on the stock price may be limited.